Pine Pharmaceuticals – New Outsourcing Facility

To accommodate its planned growth, Pine Pharmaceuticals, an FDA-registered 503B outsourcing facility, selected LaBella Associates to design their new 25,000 sq. ft. pharmaceutical manufacturing facility. Pine Pharmaceuticals produces a variety of compounded pharmaceutical preparations, including specialized sterile formulations used by ambulatory surgery centers, hospitals, and medical clinics, among others facilities.

The state-of-the-art facility comprises FDA CGMP-compliant and USP 797- and 800-compliant ISO level 8, 7, and 5 nonhazardous and hazardous compounding cleanrooms. Approximately 15,000 sq. ft. of the building is dedicated to manufacturing, fulfillment, and warehousing operations, while the remaining 10,000 sq. ft. houses office and employee support functions.

The new facility has been carefully sited to present a stunning first impression from the street. while offering dramatic views of the natural landscape to the east and south from office and employee facilities. Primary building materials include aluminum and glass storefront and windows with aluminum composite panel trim, insulated metal panels, and brick masonry.

Following several years of exponential growth, Pine Pharmaceuticals announced plans to triple the size of their 503B outsourcing facility with a 50,000 sq. ft. manufacturing addition to meet continued growing demand and provide enhanced service to their customers. Designed to comply with FDA CGMP standards, the expansion supports additional manufacturing, quality control, and warehousing for sterile compounded pharmaceuticals. The expansion was completed in September 2022.